Memorial Healthcare System tabs Fernandez as new CEO

Cara Livernois | | Health Exec | Management

Aurelio Fernandez has been announced as the new president and CEO of the Memorial Healthcare System, reports Sun Sentinel.

Fernandez, the current interim president and CEO of the healthcare provider, will permanently assume the new positions after a month long search to fill the position.

Fernandez has a bachelor's degree in business administration and accounting and a master's degree in health services administration from Florida International University. He also serves on the Florida Hospital Association's board of trustees.

The Memorial Healthcare System includes six hospitals, a nursing home, urgent care centers and home health services as well as being a research hub.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Radiology Business
Policies and regulations shaping radiology in 2025

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.